This report gives the answers to questions put to 117 “international prostate cancer experts” at the conference.
Here is an example question and summary of answers:
Q71. For patients with rising PSA and a local relapse detected by MRI and/or PSMA PET after RP who had no prior history of local sRT, 68% of panellists voted for treatment with RT (EBRT with or without boost to the lesion or SBRT) plus systemic therapy, 29% voted for RT of the prostatic bed with or without boost to the lesion, and 3% voted for SBRT of the lesion alone. There were six abstentions. (No consensus for any given answer option, no one voted for systemic therapy alone.)
doi.org/10.1016/j.eururo.20...
Background
Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.
Objective
To present consensus voting results for select questions from APCCC 2022.